Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Recruiting 18Completed 16Active not recruiting 11Terminated 5Not yet recruiting 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Rare Tumour 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1

Interventions

Cisplatin 122Carboplatin 120Drug Therapy 104Bevacizumab 101Capecitabine 96Oxaliplatin 95Radiotherapy 92Gemcitabine 88Paclitaxel 87tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 66Magnetic Resonance Spectroscopy 63Fluorouracil 61sintilimab 58Injections 57anlotinib 51Docetaxel 51Surgical Procedures, Operative 48130-nm albumin-bound paclitaxel 48fludarabine 45Pemetrexed 43Standard of Care 42Biopsy 42venetoclax 41Irinotecan 41lenvatinib 40Leucovorin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × alectinib × Clear all
NCT07560410 2026-05-11

Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

China Medical University Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Sarcoma

Bone Neoplasms

NCT06709274 2024-11-29

MOTION-NSCLC

Guangdong Association of Clinical Trials

Phase NA Not yet recruiting
342 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting
200 enrolled

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡